drug · oligonucleotide

LEQVIO

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.

targets

PCSK9 mRNA

all catalysts(0)

nothing on the calendar yet

Trials studying LEQVIO

phase3Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Diseaseactive not recruitingn=17,004
phase4Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Interventionrecruitingn=6,000
phase3Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Eventsactive not recruitingn=608
phase4Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemiacompletedn=1,770
phase3A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.active not recruitingn=14,012
phase2A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemiacompletedn=156
phase4Inclisiran Effectiveness in China: a Pragmatic Randomized Trialactive not recruitingn=1,590
phase4A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.completedn=402

more trials →

News(5)

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
biopharma_dive · 4d ago
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
fiercebiotech · 22d ago
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
biopharma_dive · 24d ago
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
fiercebiotech · 26d ago
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 1mo ago

brand

LEQVIO

trade names

Leqvio

generic

INCLISIRAN SODIUM

MOA

12.1 Mechanism of Action Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.

indication

1 INDICATIONS AND USAGE LEQVIO ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. ( 1 ) adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed just now

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · oligonucleotide

save

LEQVIO

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.

targets

PCSK9 mRNA

all catalysts(0)

nothing on the calendar yet

Trials studying LEQVIO

phase3Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Diseaseactive not recruitingn=17,004
phase4Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Interventionrecruitingn=6,000
phase3Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Eventsactive not recruitingn=608
phase4Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemiacompletedn=1,770
phase3A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.active not recruitingn=14,012
phase2A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemiacompletedn=156
phase4Inclisiran Effectiveness in China: a Pragmatic Randomized Trialactive not recruitingn=1,590
phase4A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.completedn=402

more trials →

News(5)

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
biopharma_dive · 4d ago
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
fiercebiotech · 22d ago
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
biopharma_dive · 24d ago
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
fiercebiotech · 26d ago
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 1mo ago

brand

LEQVIO

trade names

Leqvio

generic

INCLISIRAN SODIUM

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed just now

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

LEQVIO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying LEQVIO

News(5)

Report a data issue

comments(0)

LEQVIO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying LEQVIO

News(5)

Report a data issue

comments(0)